A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

Rajeev Gautam, Yoshiaki Nishimura, Amarendra Pegu, Martha C. Nason, Florian Klein, Anna Gazumyan, Jovana Golijanin, Alicia Buckler-White, Reza Sadjadpour, Keyun Wang, Zachary Mankoff, Stephen D. Schmidt, Jeffrey D. Lifson, John R. Mascola, Michel C. Nussenzweig and Malcolm A. Martin ()
Additional contact information
Rajeev Gautam: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Yoshiaki Nishimura: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Amarendra Pegu: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Martha C. Nason: Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Florian Klein: Laboratory of Molecular Immunology, The Rockefeller University
Anna Gazumyan: Laboratory of Molecular Immunology, The Rockefeller University
Jovana Golijanin: Laboratory of Molecular Immunology, The Rockefeller University
Alicia Buckler-White: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Reza Sadjadpour: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Keyun Wang: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Zachary Mankoff: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Stephen D. Schmidt: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Jeffrey D. Lifson: AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research
John R. Mascola: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Michel C. Nussenzweig: Laboratory of Molecular Immunology, The Rockefeller University
Malcolm A. Martin: Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Nature, 2016, vol. 533, issue 7601, 105-109

Abstract: A single injection of four anti-HIV-1-neutralizing monoclonal antibodies blocks repeated weekly low-dose virus challenges of simian/human immunodeficiency virus.

Date: 2016
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/nature17677 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:533:y:2016:i:7601:d:10.1038_nature17677

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature17677

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().